Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Single Oral Doses Study of Nerispirdine on Visual Function in Patients With Multiple Sclerosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00772525
Recruitment Status : Completed
First Posted : October 15, 2008
Last Update Posted : February 26, 2016
Sponsor:
Information provided by (Responsible Party):
Sanofi

Brief Summary:

The primary objective of the study was to evaluate the effect of Nerispirdine (50 mg or 400 mg) and placebo given orally as a single dose once a week in crossover design on latency of Visual Evoked Potentials (VEP) P100 in optic nerves.

Secondary objectives included evaluation of the effect of Nerispirdine on VEP amplitude and other visual parameters including visual acuity and contrast, as well as evaluation of the safety and tolerability of Nerispirdine in patients with Multiple Sclerosis (MS).

Contrast sensitivity and visual acuity examinations (in addition to Optical Coherence Tomography [OCT] and VEPs) were needed during the screening period for defining etiologic relationships (if non-MS related impairment) and for assessing the effect of treatment of age-related eye disease versus the MS-related vision impairment.


Condition or disease Intervention/treatment Phase
Multiple Sclerosis Optic Nerve Neuritis Drug: Nerispirdine Drug: Placebo Phase 2

Detailed Description:
The crossover design included 3 treatment periods 1 week apart and 6 treatment sequences. Study participation were to be 5 weeks.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 31 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Double-blind, Placebo-controlled, Randomized Crossover, Activity Study of Single Oral Doses of 50 mg and 400 mg Nerispirdine on Visual Function in Patients With Multiple Sclerosis
Study Start Date : September 2008
Actual Primary Completion Date : June 2009
Actual Study Completion Date : June 2009

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Sequence 1

placebo,1 day treatment period 1

50 mg Nerispirdine, 1 day treatment period 2

400 mg Nerispirdine, 1 day treatment period 3

Drug: Nerispirdine

form: tablet

Route: oral

Other Name: HP184

Drug: Placebo

form: tablet

Route: oral


Experimental: Sequence 2

placebo,1 day treatment period 1

400 mg Nerispirdine, 1 day treatment period 2

50 mg Nerispirdine, 1 day treatment period 3

Drug: Nerispirdine

form: tablet

Route: oral

Other Name: HP184

Drug: Placebo

form: tablet

Route: oral


Experimental: Sequence 3

50 mg Nerispirdine, 1 day treatment period 1

placebo, 1 day treatment period 2

400 mg Nerispirdine, 1 day treatment period 3

Drug: Nerispirdine

form: tablet

Route: oral

Other Name: HP184

Drug: Placebo

form: tablet

Route: oral


Experimental: Sequence 4

50 mg Nerispirdine, 1 day treatment period 1

400 mg Nerispirdine, 1 day treatment period 2

placebo, 1 day treatment period 3

Drug: Nerispirdine

form: tablet

Route: oral

Other Name: HP184

Drug: Placebo

form: tablet

Route: oral


Experimental: Sequence 5

400 mg Nerispirdine, 1 day treatment period 1

placebo, 1 day treatment period 2

50 mg Nerispirdine, 1 day treatment period 3

Drug: Nerispirdine

form: tablet

Route: oral

Other Name: HP184

Drug: Placebo

form: tablet

Route: oral


Experimental: Sequence 6

400 mg Nerispirdine, 1 day treatment period 1

50 mg Nerispirdine, 1 day treatment period 2

placebo, 1 day treatment period 3

Drug: Nerispirdine

form: tablet

Route: oral

Other Name: HP184

Drug: Placebo

form: tablet

Route: oral





Primary Outcome Measures :
  1. Visual Evoked Potential (P100) latency [ Time Frame: pre-dose and post-dose of each treatment intake (3) ]

Secondary Outcome Measures :
  1. Pelli-Robson Contrast Sensitivity Score [ Time Frame: pre-dose and post-dose of each treatment intake (3) ]
  2. Early Treatment Diabetic Retinopathy Study (EDTRS) visual acuity score [ Time Frame: pre-dose and post-dose of each treatment intake (3) ]
  3. Visual Evoked Potential (VEP) amplitude [ Time Frame: pre-dose and post-dose of each treatment intake (3) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Clinically definite MS (McDonald criteria), which includes patients with remitting-relapsing, secondary progressive, progressive-relapsing, or primary progressive MS who have had a past history of Optic Neuritis.

Exclusion Criteria:

  • Multiple sclerosis exacerbation within 60 days of the Screening Visit and the relapse involved the visual fields or visual acuity
  • No eye with appropriate degree of lesions for this study as defined by criteria based on degree of visual acuity deficit, refractive error, VEP P100 latency and average retinal nerve fiber layer thickness of as measured by Optical Coherence Tomography (OCT)
  • Any MS-unrelated prior ophthalmological impairment (eg, compressive, ischemic, toxic, or nutritional optic neuropathies, Leber's hereditary optic atrophy)
  • Previously exposed to 3,4-diaminopyridine or 4-aminopyridine

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00772525


Locations
Layout table for location information
United States, New Jersey
Sanofi-Aventis Administrave Office
Bridgewater, New Jersey, United States, 08807
Sponsors and Collaborators
Sanofi
Investigators
Layout table for investigator information
Principal Investigator: Robert SERGOTT, MD Wills Eye Institute, Thomas Jefferson University, Philadelphia Pennsylvania, USA

Layout table for additonal information
Responsible Party: Sanofi
ClinicalTrials.gov Identifier: NCT00772525     History of Changes
Other Study ID Numbers: ACT10573
First Posted: October 15, 2008    Key Record Dates
Last Update Posted: February 26, 2016
Last Verified: January 2016

Keywords provided by Sanofi:
Visual acuity
Contrast sensitivity
Visual Evoked Potentials
Optical Coherence Tomography

Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Sclerosis
Neuritis
Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Peripheral Nervous System Diseases
Neuromuscular Diseases